SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 253 filers reported holding SAGE THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $311,000 | -53.7% | 1,955 | -72.1% | 0.02% | -62.7% |
| Q4 2018 | $671,000 | +18.8% | 7,000 | +75.0% | 0.05% | +64.5% |
| Q3 2018 | $565,000 | -9.7% | 4,000 | 0.0% | 0.03% | -13.9% |
| Q2 2018 | $626,000 | -35.2% | 4,000 | -33.3% | 0.04% | -28.0% |
| Q1 2018 | $966,000 | -58.1% | 6,000 | -57.1% | 0.05% | -52.8% |
| Q4 2017 | $2,306,000 | +85.1% | 14,000 | -30.0% | 0.11% | +92.7% |
| Q3 2017 | $1,246,000 | -35.6% | 20,000 | -17.7% | 0.06% | -32.9% |
| Q2 2017 | $1,936,000 | -45.1% | 24,300 | -51.1% | 0.08% | -54.2% |
| Q1 2017 | $3,528,000 | -60.4% | 49,650 | -67.5% | 0.18% | -37.2% |
| Q4 2015 | $8,919,000 | – | 152,985 | – | 0.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |